05-05-2025
Iraqi researcher files US patent for novel immune-based Autism treatment approach
Baghdad ( – Iraqi researcher Dr. Adel Al-Salhi has filed a provisional patent application in the United States for an innovative, experimental treatment concept targeting specific immune-related subtypes of Autism Spectrum Disorder (ASD). Dr. Al-Salhi holds psychology degrees from Baghdad and Mustansiriya Universities and a PhD focused on ASD from Sigmund Freud University, Vienna.
Developed over two and a half years through extensive analysis of immunological and neurological research, the concept proposes a novel neuro-immunological regulatory approach. It specifically targets biological pathways believed to be involved in certain ASD cases with underlying immune dysregulation, aiming to address potential root causes rather than just symptoms.
Dr. Al-Salhi strongly emphasizes that this is currently a pre-clinical concept based on a scientific hypothesis, not an approved or available treatment, and has not yet been tested on humans. The provisional patent application (filed April 13, 2025, with the USPTO) protects the intellectual property as research progresses.
Plans are underway to form a specialized Iraqi team for initial pre-clinical laboratory studies. While not claiming a cure for all autism, Dr. Al-Salhi hopes this rigorously developed Iraqi innovation may eventually offer new hope for specific subgroups within the autism spectrum.
